Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 13;28(5):993–1003. doi: 10.1158/1078-0432.CCR-21-2498

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. High pAKT levels are associated with enriched benefit of ipatasertib treatment. A, Bar plot showing the pCR in the IPAT+PAC versus PBO+PAC arms, among different biomarker-selected patient subpopulations. B, Bar plot showing the ORR (MRI) in the IPAT+PAC versus PBO+PAC arms, among different biomarker-selected patient subpopulations. Darker color indicates CR and lighter color indicates PR. C, Analysis showing the ORR (MRI) in the pAKT-low and pAKT-high, among the NGS/IHC biomarker subgroups. NGS/IHC biomarker negative: PIK3CA/AKT1/PTEN nonaltered and PTEN intact; NGS/IHC biomarker positive: PIK3CA/AKT1/PTEN altered and/or PTEN low. 95% CI, 95% confidence interval; ITT, intention-to-treat. — High pAKT levels are associated with enriched benefit of ipatasertib treatment. A, Bar plot showing the pCR in the IPAT+PAC versus PBO+PAC arms, among different biomarker-selected patient subpopulations. B, Bar plot showing the ORR (MRI) in the IPAT+PAC versus PBO+PAC arms, among different biomarker-selected patient subpopulations. Darker color indicates CR and lighter color indicates PR. C, Analysis showing the ORR (MRI) in the pAKT-low and pAKT-high, among the NGS/IHC biomarker subgroups. NGS/IHC biomarker negative: PIK3CA/AKT1/PTEN nonaltered and PTEN intact; NGS/IHC biomarker positive: PIK3CA/AKT1/PTEN altered and/or PTEN low. 95% CI, 95% confidence interval; ITT, intention-to-treat.